| Literature DB >> 27196086 |
Vasilii B Doronin1, Taisiya A Parkhomenko2, Massimiliano Castellazzi3, Edward Cesnik3, Valentina N Buneva2,4, Enrico Granieri3, Georgy A Nevinsky2,4.
Abstract
We have recently shown that IgGs from serum and cerebrospinal fluid (CSF) of MS patients are active in hydrolysis of DNA and myelin basic protein. According to literature data, anti-DNA and anti-MBP abzymes may promote important neuropathologic mechanisms in this chronic inflammatory disorder and in MS pathogenesis development. At the same time, the involvement of antibodies with amylase activity in the pathogenesis of any autoimmune disease has not yet been identified. Electrophoretically and immunologically homogeneous IgGs were obtained by a sequential affinity chromatography of the CSF proteins on protein G-Sepharose and FPLC gel filtration. We are able to present the first unpredictable evidence showing that IgGs from CSF possess amylase activity and efficiently hydrolyze maltoheptaose; their average specific Ab activity is ~30-fold higher than that of antibodies from sera of the same MS patients. Specific average RA (SAA) for IgGs from healthy volunteers was approximately ~1000 lower than that for MS patients. In addition, it was shown that a relative SAA of total proteins of CSF (including Abs) ~15-fold lower than that for purified IgGs, while the relative SAA of the total sera protein is higher than that of sera IgGs by a factor of 1033. This result speaks in favor of the fact that amylolytic activity of CSF proteins is mainly caused by the activity of amylase abzymes. One cannot exclude, that amylase abzymes of CSF can play a, as yet unknown, role in the pathogenesis of MS. Some possible reasons of these findings are discussed.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27196086 PMCID: PMC4873009 DOI: 10.1371/journal.pone.0154688
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Several different characteristics of MS patients.
| Number of patient | Sex | Age, years | Clinical course | Clinical activity | MRI activity |
|---|---|---|---|---|---|
| 1 | male | 59 | PP | yes | yes |
| 2 | female | 28 | RR | no | no |
| 3 | female | 36 | RR | yes | yes |
| 4 | male | 26 | RR | yes | no |
| 5 | male | 49 | RR | no | no |
| 6 | female | 20 | RR | yes | no |
| 7 | female | 46 | PP | yes | no |
| 8 | female | 51 | RR | yes | yes |
| 9 | female | 31 | RR | yes | no |
| 10 | female | 26 | RR | no | no |
| 11 | female | 43 | RR | yes | yes |
| 12 | male | 45 | RR | yes | no |
| 13 | female | 30 | RR | no | yes |
| 14 | female | 60 | RR | yes | no |
| 15 | female | 34 | RR | yes | yes |
*Relapsing–remitting (RR) and primary progressive (PP) MS.
**Clinical activity = presence of relapse at the time of sampling.
ξMRI activity = presence or absence gadolinium enhancing lesions at MRI examination.
The relative concentration of total proteins and total IgGs purified from sera and CSF of different MS patients*.
| Number of patient | Relative concentration of total proteins, mg/ml | Relative concentration of total IgGs x 102, mg/ml | ||
|---|---|---|---|---|
| CSF | Serum | CSF | Serum | |
| 1 | 0.55 | 59 | 11.4 | 1190 |
| 2 | 0.33 | 63 | 1.9 | 925 |
| 3 | 0.26 | 72 | 3.2 | 1280 |
| 4 | 0.51 | 63 | 6.0 | 1160 |
| 5 | 0.64 | 48 | 6.4 | 1060 |
| 6 | 0.58 | 64 | 4.6 | 1140 |
| 7 | 0.56 | 64 | 11.3 | 1080 |
| 8 | 0.66 | 74 | 13.6 | 1450 |
| 9 | 0.37 | 73 | 7.5 | 1660 |
| 10 | 0.39 | 60 | 3.4 | 1010 |
| 11 | 0.42 | 58 | 2.4 | 1490 |
| 12 | 0.53 | 77 | 5.0 | 995 |
| 13 | 0.39 | 57 | 2.5 | 1000 |
| 14 | 0.47 | 58 | 9.0 | 1260 |
| 15 | 0.48 | 47 | 2.2 | 787 |
| Average value | 0.48±0.09 | 62.0±6.7 | 6.0±3.1 | 1166±178 |
*For each value, a mean of three measurements is reported; the error of the determination of values did not exceed 7–10%.
**Average values are reported as mean ± S.E.
Fig 1SDS-PAGE analysis of homogeneity of csf-IgGmix (7 μg; lanes 2 and 3) corresponding to 15 CSFs of MS patients in 3–16% gradient gel before (lane 2) and after treatment with DTT (lane 4) followed by silver staining (A). Lanes 2 and 3 correspond to Western-blotting; Abs against human amylase were used in the case of IgG (lane 2) and human amylase (lane 3). The arrows (lane SP) indicate the positions of molecular mass markers. FPLC gel filtration of csf-IgGmix on a Superdex 200 column in an acidic buffer (pH 2.6) destroying immunocomplexes after Abs incubation in the same buffer (B): (—), absorbance at 280 nm (A280); (□), relative activity (RA) of IgGs in the hydrolysis of MHO. A complete hydrolysis of MHO was taken for 100%. In-gel assay of MHO-hydrolyzing activity of csf-IgGmix (■; 15 μg) of MS patients. The relative MHO -hydrolyzing activity (RA, %) was revealed using the extracts of 2-3-mm fragments of one longitudinal slice of the gel. The RA of IgGs corresponding to complete hydrolysis of MHO was taken for 100%. The second control longitudinal slice of the same gel was stained with Coomassie Blue (lane 1). Lane C shows positions of protein markers. TLC analysis of the hydrolysis of MHO by IgGs from CSFs of different MS patients (D). MHO (1.67 mM) was incubated for 6 h at 37°C without Abs (lanes C2) and in the presence of 0.07 mg/ml IgGmix from the plasma of healthy donors (lane C1) as well as individual IgGs (0.025 mg/ml, 2 h) from CSFs of different MS patients (lanes 1–5). The average error in the initial rate determination from three experiments did not exceed 7–10%. For details, see Materials and methods.
Relative amylase activity of total proteins and IgGs from sera and CSFs of patients with MS*.
| Number of patient | 1. Activity of plasma protein; (mM/1 h/1 mg) | 2. Activity of IgGs from the plasma; (mM/1 h/mg) ×103 | 3. Activity of CSF protein; (mM/1 h/1 mg)×103 | 4. Activity of IgGs from CSF; (mM/1 h/mg) ×103 |
|---|---|---|---|---|
| 1 | 0.30 | 0.73 | 1.1 | 6.0 |
| 2 | 0.32 | 0.23 | 0.39 | 2.5 |
| 3 | 0.36 | 0.29 | 0.35 | 3.1 |
| 4 | 0.32 | 0.57 | 0.89 | 5.1 |
| 5 | 0.24 | 0.08 | 0.33 | 1.8 |
| 6 | 0.32 | 0.10 | 0.62 | 7.4 |
| 7 | 0.32 | 0.09 | 0.67 | 8.4 |
| 8 | 0.37 | 0.2. | 0.89 | 2.4 |
| 9 | 0.37 | 0.24 | 0.46 | 17.1 |
| 10 | 0.30 | 0.18 | 0.62 | 7.1 |
| 11 | 0.29 | 0.24 | 0.40 | 17.0 |
| 12 | 0.39 | 0.23 | 0.64 | 13.8 |
| 13 | 0.29 | 0.38 | 0.52 | 19.0 |
| 14 | 0.29 | 0.46 | 0.55 | 11.8 |
| 15 | 0.24 | 0.37 | 0.6 | 11.9 |
| Average values | 0.31±0.03 | 0.30 ±0.14 | 0.6 ±0.16 | 9.0 ± 4.9 |
| Ratio of all values | ||||
| Coefficient correlation | ||||
*For each value, a mean of three measurements is reported; the error of the determination of each value does not exceed 7–10%.
Relative kcat values and correlation coefficients between these values of 15 IgGs from plasma and CSFs in the hydrolysis of MHO, DNA, and MBP*.
| Number of patient | Amylase activity of plasma IgGs; kcat, min−1 | Amylase activity of CSF IgGs; kcat, min−1 | DNase activity of plasma IgGs x 103; kcat, min−1 | DNase activity of CSF IgGs x 102; kcat, min−1 | MBP-hydrolyzing activity of plasma IgGs x 103; kcat, min−1 | MBP-hydrolyzing activity of CSF IgGs; kcat, min−1 |
|---|---|---|---|---|---|---|
| Parameter number | 1 | 2 | 3 | 4 | 5 | 6 |
| 1 | 1.84 | 15.4 | 2.7 | 8.0 | 1.7 | 0.33 |
| 2 | 0.58 | 6.3 | 0.79 | 10.9 | 0.51 | 0.044 |
| 3 | 0.73 | 7.8 | 0.54 | 11.8 | 2.0 | 0.18 |
| 4 | 1.44 | 12.9 | 1.7 | 8.2 | 5.2 | 0.17 |
| 5 | 0.20 | 4.5 | 1.6 | 8.5 | 0.44 | 0.008 |
| 6 | 0.25 | 18.7 | 1.7 | 8.2 | 14.0 | 0.1 |
| 7 | 0.23 | 21.2 | 2.0 | 8.2 | 5.9 | 0.26 |
| 8 | 0.51 | 6.1 | 2.7 | 2.0 | 5.6 | 0.53 |
| 9 | 0.61 | 43.2 | 2.6 | 1.8 | 6.8 | 0.6 |
| 10 | 0.45 | 17.9 | 1.2 | 3.2 | 6.1 | 0.3 |
| 11 | 0.61 | 42.9 | 3.2 | 18.0 | 14.0 | 0.51 |
| 12 | 0.58 | 34.8 | 1.8 | 14.0 | 10.0 | 0.72 |
| 13 | 1.0 | 48 | 0.59 | 2.6 | 0.44 | 0.06 |
| 14 | 1.16 | 29.8 | 1.8 | 9.5 | 16.0 | 0.6 |
| 15 | 0.93 | 30.0 | 1.6 | 8.3 | 7.0 | 0.81 |
| Average values | 0.74±0.36 | 22.6±12.4 | 1.77±0.59 | 8.2±3.1 | 0.0064±0.0042 | 0.35±0.22 |
| Correlation coefficient | ||||||
*For each value, a mean of three measurements is reported; the error of the determination of each value does not exceed 7–10%.